Skip to main content
Open Hunch It
SYK · Medical Devices & Equipment · Healthcare

Stryker Corporation

$312.39−2.0%Close 11/12 · Next earnings Jan 28, 2027
Compare SYK with another stock
Growing?
Yes: revenue up 8% on a year earlier (quarter ended Sep 2026); earnings per share up 23% over the last four quarters.
Expensive?
Cheaper than usual: 33.3× trailing earnings; its five-year median is 41.9×. Priced 34% above the peer median of 24.8x.
Analysts?
73% of 30 say buy; average 12-month target $340, 9% above today's price.
Risky?
About average for a large company: its price swung 33% over the past year (the S&P 500's 14%), and it fell as much as 33% since Nov 2021.
Market cap$118.9B
Revenue (TTM)$26.3B
Net income (TTM)$3.6B
P/E (trailing)33.3x
52-week closing range$270 – $387
Forward P/E19.2x

Stryker is a medical technology company that sells orthopaedic implants, surgical equipment, endoscopy systems, and neurotechnology products; it primarily generates revenue from the sale of medical devices/consumables and related capital equipment (with associated service/support) to hospitals and clinicians.

More about Stryker

Market Position

Stryker is a large-scale, diversified medtech supplier with differentiated platforms such as Mako SmartRobotics (robotic-assisted orthopaedic surgery), and it competes across orthopaedics, surgical/medical equipment, endoscopy, and neurovascular/neurosurgical markets through a broad portfolio and hospital relationships.

Key Segments

Stryker reports two operating segments: MedSurg and Neurotechnology and Orthopaedics (renamed from Orthopaedics and Spine).

How has the stock done?

Over the past year SYK fell 15.0%; the health care ETF (XLV) rose 22.9% and the S&P 500 rose 10.8%.

SYK −15.0%Health care ETF (XLV) +22.9%Earnings released
How much it movesRisk
Biggest fall
−33%

From Jul 25, 2025 to Sep 24, 2026, the deepest drop from a high since Nov 2021

Volatility, past year
33%

How much the price swings in a year; the S&P 500's was 14%

Beta, past year
0.24

When the S&P 500 moves 1%, the stock has moved about 0.2% the same way

Show the earnings releases
ReleasedQuarterRevenueEPS vs estimateStock, day after5 days after
Oct 29, 2026ended Sep 2026$6.5B (+8% vs a year earlier)$3.52 vs $3.55 (missed)−4.0%+10.2%
Jul 30, 2026ended Jun 2026$6.6B (+9% vs a year earlier)$3.69 vs $3.49 (beat)−7.5%−4.2%
Apr 30, 2026ended Mar 2026$6.0B (+3% vs a year earlier)$2.60 vs $2.98 (missed)−6.5%−6.6%
Jan 29, 2026ended Dec 2025$7.2B (+11% vs a year earlier)$4.47 vs $4.40 (beat)+3.3%+1.3%
Oct 30, 2025ended Sep 2025$6.1B (+10% vs a year earlier)—−3.6%−4.3%
Jul 31, 2025ended Jun 2025$6.0B (+11% vs a year earlier)—−5.6%−6.0%
May 1, 2025ended Mar 2025$5.9B (+12% vs a year earlier)—+1.1%+2.3%
Jan 28, 2025ended Dec 2024$6.4B (+11% vs a year earlier)—−2.2%−1.9%
Oct 29, 2024ended Sep 2024$5.5B (+12% vs a year earlier)—+2.1%+3.9%
Jul 30, 2024ended Jun 2024$5.4B (+9% vs a year earlier)—−1.7%−3.2%
Apr 30, 2024ended Mar 2024$5.2B (+10% vs a year earlier)—−3.2%−2.0%
Jan 30, 2024ended Dec 2023$5.8B (+12% vs a year earlier)—+6.7%+8.0%
Nov 2, 2023ended Sep 2023$4.9B (+10% vs a year earlier)—+1.5%−0.4%
Aug 3, 2023ended Jun 2023$5.0B (+11% vs a year earlier)—+3.3%+3.1%
May 1, 2023ended Mar 2023$4.8B (+12% vs a year earlier)—−1.9%−3.8%
Jan 31, 2023ended Dec 2022$5.2B (+11% vs a year earlier)—+11.8%+9.2%
Oct 31, 2022ended Sep 2022$4.5B (+8% vs a year earlier)—−4.0%−6.9%
Jul 26, 2022ended Jun 2022$4.5B (+5% vs a year earlier)—+5.1%+5.8%
Apr 28, 2022ended Mar 2022$4.3B (+8% vs a year earlier)—−3.2%−3.1%
Jan 27, 2022ended Dec 2021$4.7B (+10% vs a year earlier)—+0.1%+1.0%

Change in closing price from the first day shown, or with Price the closing price itself. Prices: Yahoo Finance, to Nov 12, 2026. Dashed lines: the days the company released earnings (its SEC 8-K filings); EPS estimates: Yahoo Finance. The stock's move after a release runs from the last close before its day to the close the day after (or five days after), so a release before the open counts like one after the close.

Is the business growing?

Revenue was $6.5B in the quarter ended Sep 2026, up 8% from a year earlier.

Revenue by quarter
Change from the same quarter a year earlier
Show the data
Quarter endedRevenuevs a year earlier
Dec 2022$5.2B+11%
Mar 2023$4.8B+12%
Jun 2023$5.0B+11%
Sep 2023$4.9B+10%
Dec 2023$5.8B+12%
Mar 2024$5.2B+10%
Jun 2024$5.4B+9%
Sep 2024$5.5B+12%
Dec 2024$6.4B+11%
Mar 2025$5.9B+12%
Jun 2025$6.0B+11%
Sep 2025$6.1B+10%
Dec 2025$7.2B+11%
Mar 2026$6.0B+3%
Jun 2026$6.6B+9%
Sep 2026$6.5B+8%
Revenue by regionFiscal years, from Stryker's 10-K

In the fiscal year to Dec 2025, United States was 76% and Europe, Middle East, Africa was 13% of revenue.

United StatesEurope, Middle East, AfricaAsia PacificOther foreign countries
Show the data
Fiscal yearPartRevenueShare
FY2023United States$15.3B74%
FY2023Europe, Middle East, Africa$2.6B13%
FY2023Asia Pacific$1.9B9%
FY2023Other foreign countries$677M3%
FY2024United States$16.9B75%
FY2024Europe, Middle East, Africa$2.9B13%
FY2024Asia Pacific$2.0B9%
FY2024Other foreign countries$735M3%
FY2025United States$19.0B76%
FY2025Europe, Middle East, Africa$3.2B13%
FY2025Asia Pacific$2.2B9%
FY2025Other foreign countries$765M3%
Earnings per shareDiluted, GAAP
EPS, quarter ended Sep 2026
$1.96−12% on a year earlier

A year earlier $2.22

EPS, last four quarters
$9.39+23% on the four before

Diluted, from SEC filings

PEG, on the last year's growth
1.4

The P/E of 33.3× over the 23% EPS growth of the last four quarters; near 1 or below is cheap for the growth

Quarters: Stryker Corporation's SEC filings, named by the month they end. Fiscal years: Stryker Corporation's annual reports to the SEC.

How it makes money

Of every $100 in revenue, $12.9 ends up as net income. Net margin was roughly flat over the past 3 years.

Where each $1 of revenue goesFiscal year ended 2025-12-31
RevenueGross profitOperating incomeNet income
Revenue
Total sales
$25.1B100%
Gross profit
Revenue minus direct costs
$16.1B64.0% of revenue
Cost of revenue
Direct cost of making or buying goods
$9.0B36.0% of revenue
Operating income
Profit from the core business
$4.9B19.5% of revenue
Operating expenses
R&D, marketing and admin
$11.2B44.5% of revenue
Net income
What is left for shareholders after tax
$3.2B12.9% of revenue
Taxes & other
Income tax and non-operating items
$1.7B6.6% of revenue
Margins by quarter
Gross 65.2%Operating 15.9%Net 11.5%
Show the data
Quarter endedGrossOperatingNet
Dec 202262.2%15.6%10.8%
Mar 202363.1%15.4%12.4%
Jun 202363.7%19.3%14.8%
Sep 202364.3%19.0%14.1%
Dec 202363.7%21.6%19.7%
Mar 202463.6%18.5%15.0%
Jun 202463.0%19.4%15.2%
Sep 202464.0%19.7%15.2%
Dec 202464.9%9.0%8.5%
Mar 202563.8%14.3%11.1%
Jun 202563.8%18.5%14.7%
Sep 202563.6%18.7%14.2%
Dec 202564.5%25.2%11.8%
Mar 202663.3%15.5%12.4%
Jun 202668.3%25.2%19.4%
Sep 202665.2%15.9%11.5%

Circled: Dec 2025 (net 11.8%, operating 25.2%). Net margin is usually about 4 points below operating margin; in that quarter something below operating income (a tax charge or benefit, a gain or loss on investments, a write-down) moved it, not the business itself.

Gross margin, fiscal year
64.0%

+1.2 pts over 3 years

Operating margin, fiscal year
19.5%

+4.1 pts over 3 years

Net margin, fiscal year
12.9%

Roughly flat over 3 years

Each margin is that line of the income statement divided by revenue. Fiscal year: Stryker Corporation's annual reports to the SEC; quarters: SEC filings.

How much goes into research?

Stryker spent $1.7B on research and development in the four quarters to Sep 2026, 6.4% of its revenue, against 6.5% a year earlier. Over the year its research spending rose 6.4% and its revenue rose 7.9%.

Research and development, last four quarters
$1.7B

Up 6.4% on the four quarters before

Share of revenue, last four quarters
6.4%

6.5% a year earlier

Research as a share of revenue over five years, with Abbott Laboratories and Medtronic
Stryker 6.4%Abbott Laboratories 6.9%Medtronic 7.8%
Research and developmentBy quarter
Show the data
Quarter endedResearch and developmentRevenueShare of revenue, four quarters
Dec 2023$350M$5.8B6.8%
Mar 2024$368M$5.2B6.8%
Jun 2024$363M$5.4B6.7%
Sep 2024$377M$5.5B6.6%
Dec 2024$358M$6.4B6.5%
Mar 2025$405M$5.9B6.5%
Jun 2025$407M$6.0B6.5%
Sep 2025$410M$6.1B6.5%
Dec 2025$401M$7.2B6.5%
Mar 2026$413M$6.0B6.5%
Jun 2026$434M$6.6B6.4%
Sep 2026$433M$6.5B6.4%

From Stryker Corporation's SEC filings: research and development expense by quarter, the fourth being the year minus nine months; its share is the four quarters' expense over their revenue. Some companies count the research they buy, through licences and acquisitions, in this line, so it jumps in the quarter they pay; others report that on a line of its own, not shown here.

Is it expensive?

P/E of 33.3x, above the peer median of 24.8x, so it needs earnings to keep growing to hold up.

33.3×P/E (trailing)

Priced 34% above the peer median of 24.8x.

Vs. peersP/E, trailing (x)
SYKPeersPeer median 24.8x
Show the data
CompanyP/E (trailing)
EW · Edwards Lifesciences Corporation61.5×
ABT · Abbott Laboratories39.9×
SYK · Stryker Corporation33.3×
MDT · Medtronic plc24.8×
BSX · Boston Scientific Corporation18.7×
GEHC · GE HealthCare Technologies Inc.17.3×
Against its own past five yearsTrailing P/E

At 33.3× trailing earnings SYK is below most of its five-year range; the five-year median is 41.9×.

Trailing P/EMiddle half of five years 38.9×–47.6×Median 41.9×
Show the data
DateTrailing P/E
Nov 8, 202155.4×
Feb 8, 202249.0×
May 10, 202243.3×
Aug 10, 202240.4×
Nov 8, 202232.6×
Feb 9, 202342.8×
May 11, 202341.5×
Aug 11, 202339.8×
Nov 9, 202340.2×
Feb 12, 202441.3×
May 13, 202437.1×
Aug 13, 202436.7×
Nov 11, 202440.6×
Feb 13, 202550.0×
May 15, 202553.0×
Aug 15, 202550.6×
Nov 13, 202549.1×
Feb 17, 202643.9×
May 18, 202636.3×
Aug 18, 202634.3×
Nov 12, 202633.3×

Closing price over diluted earnings per share of the last four reported quarters, as known on each day (a quarter counts 35 days after it ends). From SEC filings; earnings per share adjusted for splits.

What analysts expect

The average analyst price target is $340, 9% above the current price; 73% of 30 analysts rate it a buy; earnings beat estimates in 2 of the last 4 quarters.

12-month price targetsCurrent price $312.39
12 mo agoTodayIn 12 mo
High target
$465+49%
Average target
$340+9%
Low target
$275−12%
Ratings30 analysts
Strong Buy 8Buy 14Hold 8Sell 0Strong Sell 0

Buy or Strong Buy: 22 analysts (73%). Sell or Strong Sell: 0.

Targets and ratings over the past year58 changes by 20 firms

Over the past year the average of the analysts' latest price targets went from $428.50 to $341.38 (−20%), while SYK went from $373.42 to $312.39 (−16%). In the past three months targets were raised once and cut 19 times. 1 upgrade and 2 downgrades over the year; the latest: Canaccord Genuity moved it to Hold from Buy on Oct 30, 2026.

Average target $341.38SYKMiddle half of targetsUpgradeDowngrade
Targets raised, by monthTargets cut
Show every change
DateFirmChangeRatingTarget
Nov 9, 2026Piper SandlerTarget raisedOverweight$350.00, was $325.00
Nov 2, 2026Truist SecuritiesTarget cutHold$305.00, was $310.00
Nov 2, 2026StifelTarget cutBuy$325.00, was $330.00
Oct 31, 2026JP MorganTarget cutOverweight$340.00, was $350.00
Oct 30, 2026CitigroupTarget cutBuy$315.00, was $360.00
Oct 30, 2026TD CowenTarget cutHold$290.00, was $298.00
Oct 30, 2026RBC CapitalTarget cutOutperform$375.00, was $420.00
Oct 30, 2026BarclaysTarget cutOverweight$365.00, was $375.00
Oct 30, 2026Canaccord GenuityDowngradeHold, was Buy$300.00, was $385.00
Oct 30, 2026CitizensTarget cutMarket Outperform$390.00, was $400.00
Oct 30, 2026Evercore ISI GroupTarget cutOutperform$320.00, was $335.00
Oct 30, 2026NeedhamTarget cutBuy$359.00, was $418.00
Oct 30, 2026BTIGTarget cutBuy$304.00, was $316.00
Oct 12, 2026BTIGTarget cutBuy$316.00, was $358.00
Oct 7, 2026Truist SecuritiesTarget cutHold$310.00, was $340.00
Oct 7, 2026BarclaysBegan coverageOverweight$375.00
Sep 30, 2026StifelTarget cutBuy$330.00, was $360.00
Sep 22, 2026TD CowenTarget cutHold$298.00, was $355.00
Sep 18, 2026Canaccord GenuityTarget cutBuy$385.00, was $400.00
Sep 10, 2026CitigroupTarget cutBuy$360.00, was $399.00
Sep 9, 2026Wells FargoTarget cutOverweight$348.00, was $418.00
Aug 13, 2026Wolfe ResearchDowngradePeer Perform, was Outperform—
Aug 3, 2026CitizensTarget cutMarket Outperform$400.00, was $440.00
Jul 31, 2026RBC CapitalTarget cutOutperform$420.00, was $435.00
Jul 31, 2026JP MorganTarget cutOverweight$350.00, was $400.00
Jul 31, 2026Piper SandlerTarget cutOverweight$390.00, was $420.00
Jul 31, 2026Truist SecuritiesTarget raisedHold$340.00, was $330.00
Jul 31, 2026BTIGTarget cutBuy$358.00, was $371.00
Jul 9, 2026BMO CapitalBegan coverageOutperform, was Market Perform$369.00
Jul 6, 2026Evercore ISI GroupTarget cutOutperform$350.00, was $355.00
Jun 5, 2026Leerink PartnersTarget cutOutperform$407.00, was $410.00
May 4, 2026Truist SecuritiesTarget cutHold$330.00, was $380.00
May 4, 2026BarclaysTarget cutOverweight$394.00, was $469.00
May 1, 2026Canaccord GenuityTarget cutBuy$400.00, was $435.00
May 1, 2026JP MorganTarget cutOverweight$400.00, was $445.00
May 1, 2026Evercore ISI GroupTarget cutOutperform$355.00, was $365.00
May 1, 2026Wells FargoTarget cutOverweight$418.00, was $456.00
May 1, 2026NeedhamTarget cutBuy$418.00, was $454.00
May 1, 2026BTIGTarget cutBuy$379.00, was $397.00
Apr 15, 2026Truist SecuritiesTarget cutHold$380.00, was $395.00
Apr 14, 2026BTIGTarget keptBuy$397.00
Apr 13, 2026Leerink PartnersBegan coverageOutperform$410.00
Apr 9, 2026Goldman SachsTarget cutNeutral$357.00, was $403.00
Apr 7, 2026CitigroupTarget cutBuy$385.00, was $420.00
Apr 6, 2026Evercore ISI GroupTarget cutOutperform$365.00, was $400.00
Mar 17, 2026UBSTarget cutNeutral$380.00, was $400.00
Feb 24, 2026UBSTarget raisedNeutral$400.00, was $386.00
Feb 2, 2026BarclaysTarget raisedOverweight$469.00, was $462.00
Jan 30, 2026NeedhamTarget raisedBuy$454.00, was $448.00
Jan 30, 2026BTIGTarget raisedBuy$412.00, was $410.00
Jan 9, 2026BernsteinTarget raisedOutperform$465.00, was $450.00
Dec 19, 2025CitizensUpgradeMarket Outperform, was Market Perform$440.00
Dec 18, 2025Truist SecuritiesTarget cutHold$392.00, was $400.00
Dec 11, 2025CitigroupTarget cutBuy$420.00, was $455.00
Nov 14, 2025Truist SecuritiesTarget raisedHold$400.00, was $392.00
Nov 14, 2025Wells FargoTarget raisedOverweight$456.00, was $452.00
Nov 14, 2025NeedhamTarget keptBuy$448.00
Nov 14, 2025BTIGTarget keptBuy$410.00
Earnings against estimatesLast 4 quarters, per share
Average estimateReported, beatReported, missed
Show the data
QuarterEstimateReportedSurprise
Dec ’25$4.40$4.47+1.6%
Mar ’26$2.98$2.60−12.8%
Jun ’26$3.49$3.69+5.7%
Sep ’26$3.55$3.52−0.8%

The day after each of these reports the stock moved +3.3% (Dec 2025, beat); −6.5% (Mar 2026, missed); −7.5% (Jun 2026, beat); −4.0% (Sep 2026, missed).

Expected nextConsensus of Nov 10, 2026

For the quarter ending Dec 2026 (Stryker reports on Jan 28, 2027), analysts expect adjusted earnings of $5.02 a share, 12% more than the $4.47 of a year earlier, and revenue of $7.7B, up 7% on a year earlier. For the fiscal year ending Dec 2027, they expect adjusted earnings of $16.29 a share, 10% more than the year before's estimate of $14.83, and revenue of $28.8B, up 7% on the year before's estimate.

EPS, quarter ending Dec 2026
$5.02+12% on a year earlier

Adjusted. Dec 2025: $4.47; range $4.99 to $5.05; 25 analysts

Revenue, quarter ending Dec 2026
$7.7B+7% on a year earlier

Dec 2025: $7.2B; range $7.6B to $7.8B; 24 analysts

EPS, year ending Dec 2027
$16.29+10% on the year before's estimate

Adjusted. The year to Dec 2026: $14.83 expected; range $16.00 to $16.51; 29 analysts

Revenue, year ending Dec 2027
$28.8B+7% on the year before's estimate

The year to Dec 2026: $26.8B expected; range $28.3B to $31.8B; 28 analysts

Show the data
PeriodFigureExpectedLow to highAnalystsA year earlierChange
Quarter ending Dec 2026, results Jan 28, 2027EPS (adjusted)$5.02$4.99 to $5.0525$4.47 (Dec 2025)+12%
Quarter ending Dec 2026, results Jan 28, 2027Revenue$7.7B$7.6B to $7.8B24$7.2B (Dec 2025)+7%
Quarter ending Mar 2027EPS (adjusted)$3.18$2.83 to $3.6316$2.60 (Mar 2026)+22%
Quarter ending Mar 2027Revenue$6.5B$6.4B to $6.7B14$6.0B (Mar 2026)+8%
Year ending Dec 2026EPS (adjusted)$14.83$14.80 to $14.8829——
Year ending Dec 2026Revenue$26.8B$26.7B to $26.9B26$25.1B (year to Dec 2025)+7%
Year ending Dec 2027EPS (adjusted)$16.29$16.00 to $16.5129$14.83 (expected, year to Dec 2026)+10%
Year ending Dec 2027Revenue$28.8B$28.3B to $31.8B28$26.8B (expected, year to Dec 2026)+7%

Targets, ratings and earnings estimates: Yahoo Finance. Rating and target changes: Yahoo Finance's list of upgrades and downgrades. The average target on each day is the average of every listed firm's latest target set in the 180 days before it, so it counts fewer analysts than the average target above, and the band is the middle half of those targets (a quarter of the firms are above it, a quarter below); a target set before a stock split is divided by the split. Expected figures: the average of the analysts' estimates (Yahoo Finance). Their EPS is adjusted, as analysts estimate it, so it is set against the adjusted EPS Yahoo reports for the same quarters, not the GAAP EPS of the growth and valuation sections; revenue against the SEC filings. No change is given against a quarter whose reported EPS was more than 50% off its own estimate (often a one-off gain or charge), nor against a year that counts one. Each estimate is pinned to its fiscal period by the report date or the period's end, and one that cannot be is left out.

Where the cash goes

Generated $4.6B in free cash flow over the year, of which $1.4B went back to shareholders (dividends plus buybacks), leaving $3.2B in the company.

Where a year of cash went4 quarters to Sep 2026
Show the data
LineAmount
Op. cash flow$5.4B
Capex−$800M
Free cash flow$4.6B
Dividends−$1.3B
Buybacks−$100M
Cash retained$3.2B
Free cash flow yield
3.9%

For every $100 of market cap, the company generates about $3.9 in free cash flow a year.

Dividend yield
1.1%

For every $100 of market cap, you receive about $1.1 in dividends a year.

By quarter: free cash flow and what went back to shareholdersLast 12 quarters
Free cash flowDividendsBuybacks
Show the data
Quarter endedFree cash flowDividendsBuybacks
Dec 2023$1.4B$285M—
Mar 2024$37M$304M—
Jun 2024$481M$305M—
Sep 2024$1.3B$305M—
Dec 2024$1.7B$305M—
Mar 2025$127M$320M—
Jun 2025$928M$321M—
Sep 2025$1.4B$322M—
Dec 2025$1.9B$321M—
Mar 2026$415M$337M—
Jun 2026$1.1B$337M—
Sep 2026$1.2B$338M—
Diluted sharesDown 0.5% in a year

Stryker had 385M diluted shares in the quarter ended Sep 2026, 0.5% fewer than a year earlier, and 0.4% more each year on average since Jun 2020. Over the last four quarters its earnings per share rose 23.4% and its net income rose 23.1%: fewer shares added about 0 points.

Show the data
Quarter endedDiluted shares
Jun 2020376M
Sep 2020380M
Mar 2021382M
Jun 2021382M
Sep 2021383M
Mar 2022383M
Jun 2022382M
Sep 2022382M
Mar 2023383M
Jun 2023384M
Sep 2023384M
Mar 2024385M
Jun 2024385M
Sep 2024386M
Mar 2025386M
Jun 2025386M
Sep 2025387M
Mar 2026386M
Jun 2026386M
Sep 2026385M

Free cash flow: operating cash flow minus capital spending on property, plant and equipment, from SEC filings, for the last 4 quarters and by quarter. Shares: each quarter's diluted weighted average as filed with the SEC, since the stock's listing and its latest split.

Financial health

Current ratio 1.9, no pressure to repay short-term debt; debt-to-equity 0.7, debt is moderate.

Current ratio
1.9Strong liquidity

Assets that can be turned into cash soon are 1.9x what is owed within a year. 1.5 or higher is comfortable; below 1 needs watching.

Debt-to-equity
0.7Moderate debt

For every $1 of shareholder funds, there is $0.7 of debt. The higher the number, the more pressure when the economy weakens.

Net debt
$11.8BMore debt than cash

Cash and short-term investments of $4.1B against debt of $15.9B.

AssetsTotal ~$47.8B
Cash
$4.0B8.4%
Investments
$90M0.2%
Receivables
$4.0B8.4%
Inventory
$5.3B11.1%
Property & equipment
$3.9B8.1%
Goodwill
$19.3B40.3%
Intangibles
$5.7B11.9%
Other
$5.5B11.6%
Liabilities & equityTotal ~$47.8B
Current
$7.8B16.3%
Long-term
$17.6B36.8%
Equity
$22.4B46.9%

Latest fiscal year balance sheet. Source: Yahoo Finance.

Who holds it

In the filings of 3 members of Congress and 8 funds whose copy leaves SYK out (not traded on the exchange): Fundsmith, Tom Kean Jr., Jared Moskowitz, Rob Bresnahan, Norges Bank, Swiss National Bank and 5 more.

What did the funds Hunch tracks do?

Of the 83 funds whose 13F filings Hunch reads, 11 held SYK at the end of their latest quarter (for most, Q2 2026). Over that quarter 2 added shares, 8 cut, 1 bought new and 2 sold all. The largest of them is Norges Bank, 4.89M shares worth $1.5B at Jun 30, 2026, 5.6% fewer than at Dec 31, 2025.

Funds that added shares
3

1 of them new holders

Funds that cut
10

2 of them sold all

Change in shares over the latest quarterThe 12 largest holdings
Added or newCut or sold all
Show every fund
FundQuarterSharesValueChange in sharesChangeFiled
Norges BankQ2 2026 vs Q4 20254.89M$1.5B−292,101−5.6%Aug 12, 2026
FundsmithQ2 20262.91M$917M−147,583−4.8%Aug 14, 2026
Swiss National BankQ3 2026943,740$260M−28,440−2.9%Nov 12, 2026
National Pension ServiceQ3 2026730,799$201M+9,613+1.3%Nov 12, 2026
Canada Pension Plan Investment BoardQ2 2026488,517$154M−60,113−11%Aug 14, 2026
Fisher Asset ManagementQ3 2026378,378$104M−17,396−4.4%Nov 6, 2026
Korea InvestmentQ2 2026170,682$53.7M−4,898−2.8%Aug 12, 2026
Renaissance TechnologiesQ3 20260—−91,300Sold allNov 12, 2026
Mirae Asset Global InvestmentsQ3 202694,280$26.0M−15,133−14%Nov 3, 2026
Baillie Gifford &Q3 202662,615$17.2M+62,615NewNov 9, 2026
Nomura HoldingsQ2 202621,150$6.7M+19,816+1485%Aug 14, 2026
Bridgewater AssociatesQ2 202612,155$3.8M−14,255−54%Aug 14, 2026
Tudor Investment Corp Et AlQ2 20260—−1,370Sold allAug 14, 2026

From the 13F filings of the 83 funds Hunch tracks, not of every institution: each fund's shares of SYK at its latest quarter end against the quarter before, as filed (long positions only, options left out), the quarter before put on the latest quarter's share count across a split. A fund files 45 days after its quarter ends, so some have a newer quarter than others. Value is at the quarter end. Norges Bank filed its 13F for Q1 2026 confidentially, with no holdings made public, so its row compares Q2 2026 with Q4 2025.

Insights that mention SYK